

Pratiti Bandopadhyay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4394943/publications.pdf>

Version: 2024-02-01

57
papers

3,570
citations

218677

26
h-index

377865

34
g-index

58
all docs

58
docs citations

58
times ranked

6574
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of patients ≤ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
2	Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. <i>Neuro-Oncology</i> , 2022, 24, 1352-1363.	1.2	29
3	HGG-36. Elucidating the role of long non-coding RNAs in pediatric high grade gliomas. <i>Neuro-Oncology</i> , 2022, 24, i68-i69.	1.2	0
4	RARE-22 Characterizing the landscape of structural variants in adamantinomatous craniopharyngioma. <i>Neuro-Oncology</i> , 2022, 24, i14-i14.	1.2	0
5	DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers. <i>Neuro-Oncology</i> , 2022, 24, i21-i22.	1.2	0
6	LGG-45. Genetic dependencies in MYB/MYBL1-driven pediatric low-grade glioma models. <i>Neuro-Oncology</i> , 2022, 24, i98-i98.	1.2	0
7	LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study. <i>Neuro-Oncology</i> , 2022, 24, i191-i192.	1.2	4
8	Abstract 3890: Sequencing of 888 pediatric solid tumors informs precision oncology trial design and data sharing initiatives in pediatric cancer. <i>Cancer Research</i> , 2022, 82, 3890-3890.	0.9	0
9	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. <i>Nature Cancer</i> , 2022, 3, 994-1011.	13.2	20
10	A first-generation pediatric cancer dependency map. <i>Nature Genetics</i> , 2021, 53, 529-538.	21.4	76
11	Abstract 1816: Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma. , 2021, , .		0
12	DDRE-14. OPTIMIZING MDM2 INHIBITION FOR THE TREATMENT OF HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi77-vi77.	1.2	0
13	CSIG-06. ELUCIDATING THE ROLE OF CO-OCCURRING MUTATIONS IN FGFR1-DRIVEN PEDIATRIC LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi34-vi34.	1.2	0
14	EPCO-21. CORE REGULATORY CIRCUIT TRANSCRIPTION FACTORS DRIVE EXPRESSION FROM HIGH LEVEL AMPLICONS IN PEDIATRIC HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi6-vi6.	1.2	0
15	NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES. <i>Neuro-Oncology</i> , 2021, 23, vi129-vi130.	1.2	0
16	TAMI-75. LIPID METABOLISM AS A THERAPEUTIC VULNERABILITY IN BET INHIBITOR-RESISTANT MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi214-vi214.	1.2	0
17	EXTH-71. FUNCTIONAL GENOMICS IDENTIFIES EPIGENETIC REGULATORS AS NOVEL THERAPEUTIC TARGETS FOR SONIC HEDGEHOG MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi179-vi179.	1.2	0
18	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	28.9	93

#	ARTICLE	IF	CITATIONS
19	MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. <i>American Journal of Neuroradiology</i> , 2020, 41, 874-881.	2.4	15
20	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. <i>Cancer Cell</i> , 2020, 37, 104-122.e12.	16.8	267
21	The "Risk" in Pediatric Low-Grade Glioma. <i>Cancer Cell</i> , 2020, 37, 424-425.	16.8	5
22	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	27.8	374
23	RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii443-iii443.	1.2	0
24	LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii373-iii373.	1.2	0
25	DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). <i>Neuro-Oncology</i> , 2020, 22, iii297-iii297.	1.2	0
26	Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. <i>Nature Communications</i> , 2019, 10, 3731.	12.8	45
27	MEDU-36. BCL2 FAMILY MEMBERS ATTENUATE RESPONSE OF MYC-DRIVEN MEDULLOBLASTOMAS TO BET-BROMODOMAIN INHIBITION. <i>Neuro-Oncology</i> , 2019, 21, ii110-ii111.	1.2	0
28	Increasing value of autopsies in patients with brain tumors in the molecular era. <i>Journal of Neuro-Oncology</i> , 2019, 145, 349-355.	2.9	6
29	Towards Immunotherapy for Pediatric Brain Tumors. <i>Trends in Immunology</i> , 2019, 40, 748-761.	6.8	77
30	DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). <i>Neuro-Oncology</i> , 2019, 21, ii70-ii71.	1.2	0
31	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	12.8	37
32	DIPG-02. TRANSLATIONAL MR IMAGING CORRELATES FOR MOLECULAR ANALYSES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , 2019, 21, ii68-ii68.	1.2	0
33	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
34	Management of pediatric low-grade glioma. <i>Current Opinion in Pediatrics</i> , 2019, 31, 21-27.	2.0	87
35	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	12.6	461
36	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. <i>Journal of Neuro-Oncology</i> , 2018, 137, 269-278.	2.9	42

#	ARTICLE	IF	CITATIONS
37	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	1.2	116
38	LGG-13. RESOLVING TRANSCRIPTIONAL PROFILES IN BRAF-REARRANGED PILOCYTIC ASTROCYTOMA USING SINGLE CELL RNA SEQUENCING. <i>Neuro-Oncology</i> , 2018, 20, i107-i107.	1.2	0
39	PATH-17. INCREASING VALUE OF AUTOPSIES IN PATIENTS WITH BRAIN TUMORS IN THE MOLECULAR ERA. <i>Neuro-Oncology</i> , 2018, 20, vi161-vi162.	1.2	0
40	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. <i>Cancer Cell</i> , 2018, 34, 922-938.e7.	16.8	63
41	DIPG-69. CHARACTERISTICS OF PATIENTS \leq 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	1.2	1
42	TBIO-18. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. <i>Neuro-Oncology</i> , 2018, 20, i184-i184.	1.2	0
43	Dual HDAC and PI3K Inhibition Abrogates NF κ B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018, 78, 4007-4021.	0.9	60
44	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	1.2	73
45	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , 2017, 19, now294.	1.2	54
46	Population Control: Cortical Interneurons Modulate Oligodendrogenesis. <i>Neuron</i> , 2017, 94, 415-417.	8.1	0
47	Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. <i>Journal of Neuro-Oncology</i> , 2017, 135, 201-211.	2.9	72
48	Tyrosine receptor kinase B is a drug target in astrocytomas. <i>Neuro-Oncology</i> , 2017, 19, 22-30.	1.2	32
49	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. <i>Neuro-Oncology</i> , 2016, 18, iii94.1-iii94.	1.2	0
50	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. <i>Cancer</i> , 2016, 122, 1261-1269.	4.1	109
51	Myxopapillary ependymomas in children: imaging, treatment and outcomes. <i>Journal of Neuro-Oncology</i> , 2016, 126, 165-174.	2.9	39
52	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. <i>Neuro-Oncology</i> , 2015, 17, 1486-1496.	1.2	39
53	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 232-237.	7.1	136
54	Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1173-1179.	1.5	210

#	ARTICLE	IF	CITATIONS
55	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 294-307.	7.4	45
56	BET Bromodomain Inhibition of <i>MYC</i> -Amplified Medulloblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 912-925.	7.0	296
57	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. <i>Nature Medicine</i> , 2014, 20, 732-740.	30.7	255